123 related articles for article (PubMed ID: 38537936)
21. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
22. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
23. Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.
Darb-Esfahani S; Kolaschinski I; Trillsch F; Mahner S; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Wienert S; Taube ET; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
Histopathology; 2018 Dec; 73(6):1002-1012. PubMed ID: 30007074
[TBL] [Abstract][Full Text] [Related]
24. Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer.
Zhang G; Xu Q; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Cancer Med; 2021 Jun; 10(12):3905-3918. PubMed ID: 33955198
[TBL] [Abstract][Full Text] [Related]
25. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy.
Bösmüller H; Haitchi-Petnehazy S; Webersinke G; Marschon R; Roithmeier F; Stummvoll W; Fehm T; Klier-Richter M; Bonzheim I; Staebler A; Fend F
Virchows Arch; 2011 Aug; 459(2):183-91. PubMed ID: 21713364
[TBL] [Abstract][Full Text] [Related]
27. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
28. High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer.
Ölmez F; Oğlak SC; Ölmez ÖF; Akbayır Ö; Yılmaz E; Akgöl S; Konal M; Seyhan NA; Kinter AK
Turk J Obstet Gynecol; 2022 Sep; 19(3):246-256. PubMed ID: 36149309
[TBL] [Abstract][Full Text] [Related]
29. Machine Learning Quantification of Intraepithelial Tumor-Infiltrating Lymphocytes as a Significant Prognostic Factor in High-Grade Serous Ovarian Carcinomas.
Machuca-Aguado J; Conde-Martín AF; Alvarez-Muñoz A; Rodríguez-Zarco E; Polo-Velasco A; Rueda-Ramos A; Rendón-García R; Ríos-Martin JJ; Idoate MA
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003250
[TBL] [Abstract][Full Text] [Related]
30. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
[TBL] [Abstract][Full Text] [Related]
31. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
Matsushita H; Hasegawa K; Oda K; Yamamoto S; Asada K; Karasaki T; Yabuno A; Nishijima A; Nejo T; Kobayashi Y; Sato S; Ikeda Y; Miyai M; Takahashi Y; Yamaguchi R; Fujiwara K; Aburatani H; Kakimi K
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461346
[TBL] [Abstract][Full Text] [Related]
32. Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma.
Townsend KN; Spowart JE; Huwait H; Eshragh S; West NR; Elrick MA; Kalloger SE; Anglesio M; Watson PH; Huntsman DG; Lum JJ
PLoS One; 2013; 8(12):e82406. PubMed ID: 24376535
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
Li J; Wang J; Chen R; Bai Y; Lu X
Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503
[TBL] [Abstract][Full Text] [Related]
34. Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma.
Hwang C; Lee SJ; Lee JH; Kim KH; Suh DS; Kwon BS; Choi KU
Oncol Lett; 2019 May; 17(5):4557-4565. PubMed ID: 30944645
[TBL] [Abstract][Full Text] [Related]
35. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
Clarke B; Tinker AV; Lee CH; Subramanian S; van de Rijn M; Turbin D; Kalloger S; Han G; Ceballos K; Cadungog MG; Huntsman DG; Coukos G; Gilks CB
Mod Pathol; 2009 Mar; 22(3):393-402. PubMed ID: 19060844
[TBL] [Abstract][Full Text] [Related]
36. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
Leonard B; Starrett GJ; Maurer MJ; Oberg AL; Van Bockstal M; Van Dorpe J; De Wever O; Helleman J; Sieuwerts AM; Berns EM; Martens JW; Anderson BD; Brown WL; Kalli KR; Kaufmann SH; Harris RS
Clin Cancer Res; 2016 Sep; 22(18):4746-55. PubMed ID: 27016308
[TBL] [Abstract][Full Text] [Related]
37. Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.
Stanske M; Wienert S; Castillo-Tong DC; Kreuzinger C; Vergote I; Lambrechts S; Gabra H; Gourley C; Ganapathi RN; Kolaschinski I; Budczies J; Sehouli J; Ruscito I; Denkert C; Kulbe H; Schmitt W; Jöhrens K; Braicu I; Darb-Esfahani S
Neoplasia; 2018 Mar; 20(3):280-288. PubMed ID: 29466768
[TBL] [Abstract][Full Text] [Related]
38. Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.
Donnem T; Hald SM; Paulsen EE; Richardsen E; Al-Saad S; Kilvaer TK; Brustugun OT; Helland A; Lund-Iversen M; Poehl M; Olsen KE; Ditzel HJ; Hansen O; Al-Shibli K; Kiselev Y; Sandanger TM; Andersen S; Pezzella F; Bremnes RM; Busund LT
Clin Cancer Res; 2015 Jun; 21(11):2635-43. PubMed ID: 25680376
[TBL] [Abstract][Full Text] [Related]
39. Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma.
Montfort A; Barker-Clarke RJ; Piskorz AM; Supernat A; Moore L; Al-Khalidi S; Böhm S; Pharoah P; McDermott J; Balkwill FR; Brenton JD
Br J Cancer; 2020 Jun; 122(12):1803-1810. PubMed ID: 32249277
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
